Page last updated: 2024-12-08
mr 16728
Description
MR 16728: structure given in first source; a cetiedil analog that enhances acetylcholine release [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]
Cross-References
| ID Source | ID |
|---|
| PubMed CID | 378811 |
| CHEMBL ID | 1378945 |
| CHEBI ID | 91621 |
| SCHEMBL ID | 194768 |
| MeSH ID | M0214455 |
Synonyms (23)
| Synonym |
|---|
| BRD-A30590053-003-01-1 |
| nsc662128 |
| n-(3-(1-azepanyl)propyl)-2-cyclohexyl-2-phenylacetamide hydrochloride |
| n-[3-(azepan-1-yl)propyl]-2-cyclohexyl-2-phenyl-acetamide |
| NCGC00024638-02 |
| mr 16728 |
| n-[3-(azepan-1-yl)propyl]-2-cyclohexyl-2-phenylacetamide |
| 147614-21-9 |
| mr16728 |
| benzeneacetamide, alpha-cyclohexyl-n-(3-(hexahydro-1h-azepin-1-yl)propyl)- |
| mr-16728 |
| n-(n'-hexamethyleneimino)propyl-2-cyclohexyl-2-phenylacetamide |
| SCHEMBL194768 |
| CHEMBL1378945 |
| CHEBI:91621 |
| n-(3-(azepan-1-yl)propyl)-2-cyclohexyl-2-phenylacetamide hydrochloride; mr 16728 hydrochloride |
| Q27163450 |
| n-[3-(1-azepanyl)propyl]-2-cyclohexyl-2-phenylacetamide |
| n-[3-(azepan-1-yl)propyl]-2-cyclohexyl-2-phenylethanimidic acid |
| DTXSID00933167 |
| n-(3-(azepan-1-yl)propyl)-2-cyclohexyl-2-phenylacetamide |
| STARBLD0047608 |
| benzeneacetamide, alpha-cyclohexyl-n-[3-(hexahydro-1h-azepin-1-yl)propyl]- |
Drug Classes (1)
| Class | Description |
|---|
| acetamides | Compounds with the general formula RNHC(=O)CH3. |
| [compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res] |
Protein Targets (3)
Potency Measurements
Research
Studies (5)
| Timeframe | Studies, This Drug (%) | All Drugs % |
|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 3 (60.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 2 (40.00) | 2.80 |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |
Market Indicators
Research Demand Index: 12.87
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.
| Metric | This Compound (vs All) |
|---|
| Research Demand Index | 12.87 (24.57) | | Research Supply Index | 1.79 (2.92) | | Research Growth Index | 4.66 (4.65) | | Search Engine Demand Index | 0.00 (26.88) | | Search Engine Supply Index | 0.00 (0.95) |
| |
Study Types
| Publication Type | This drug (%) | All Drugs (%) |
|---|
| Trials | 0 (0.00%) | 5.53% |
| Reviews | 0 (0.00%) | 6.00% |
| Case Studies | 0 (0.00%) | 4.05% |
| Observational | 0 (0.00%) | 0.25% |
| Other | 5 (100.00%) | 84.16% |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |